Home Air Pollution in Children with Cystic Fibrosis (HEROIC- CF)
HEROIC- CF
What is the goal of the study?
Cystic Fibrosis (CF) is a chronic pulmonary disease that continues to cause significant morbidity and mortality despite great advances in therapies. Over the past decade, CFTR modulators have significantly improved the prognosis for CF. However, CFTR modulators are not a cure, and people with CF continue to have significant pulmonary disease, including the severe pulmonary pathogen Pseudomonas aeruginosa does not clear with modulator therapy1. The benefits from CFTR modulators have not accrued equitably, as Hispanic cwCF are less likely to qualify for CFTR modulators than non-Hispanic white cwCF (68% vs. 87%)2,3. Even when they qualify, Hispanic cwCF are less likely to be prescribed CFTR modulators than non-Hispanic white cwCF4. Only 78% of qualified Hispanic cwCF were prescribed CFTR modulators, while 86% of qualified non-Hispanic white cwCF were prescribed CFTR modulators4. There are stark health disparities in Hispanic cwCF that were described before CFTR modulators 5-8 and have widened with unequal access to CFTR modulators 3,9. There is an urgent need to understand the factors driving health disparities in CF, which will likely continue to negatively influence health outcomes, even in those cwCF on CFTR modulators.
Who can participate in the study?
Please contact the study team listed below to learn more.